AstraZeneca PLCAZN:LSE

4,357.5
35.00 / 0.81%
3.16m
32.13%
0.3469
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 30 2014 17:09 BST.

Income statement in USD

Year on year AstraZeneca PLC's revenues fell 8.09% from 27.97bn to 25.71bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 6.24bn to 2.56bn, a 59.04% decrease. View full income statement

REVENUE
Gross margin79.80%
Net profit margin8.02%
Operating margin12.24%
NET INCOME
Return on assets3.70%
Return on equity9.37%
Return on investment5.15%

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped 1.75% and 58.71%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.

DIVIDEND PER SHARE
Div yield(5 year avg)0.09%
Div growth rate (5 year)6.43%
Payout ratio (TTM)171.60%
EARNINGS PER SHARE
EPS growth(5 years)-13.4583
EPS (TTM) vs
TTM 1 year ago
-63.5826

Cash flow in USD

In 2013, AstraZeneca PLC increased its cash reserves by 18.42%, or 1.40bn. The company earned 7.40bn from its operations for a Cash Flow Margin of 28.78%. In addition the company used 2.89bn on investing activities and also paid 3.05bn in financing cash flows. View full cash flow statement

CASH FLOW
Cash flow per share3.34
Price/Cash flow per share13.05
CASH
Book value per share10.04
Tangible book value per share-5.4651

Balance sheet in USD

AstraZeneca PLC has a Debt to Total Capital ratio of 32.50%, a lower figure than the previous year's 41.81%. View full balance sheet

TOTAL ASSETS
Current ratio0.9446
Quick ratio0.821
TOTAL DEBT
Total debt/total equity0.482
Total debt/total capital0.325
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.